Pub Date : 2023-09-26DOI: 10.14229/jadc.2023.26.020
Toshimitsu Uenaka, Ph.D
One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a particular pathogen without affecting normal host cells. Antibody drug conjugates (ADCs) are the realization of Ehrlich’s vision for therapies that target tumor cells with precision and specificity.
{"title":"Unlocking the Potential of Antibody-Drug Conjugates","authors":"Toshimitsu Uenaka, Ph.D","doi":"10.14229/jadc.2023.26.020","DOIUrl":"https://doi.org/10.14229/jadc.2023.26.020","url":null,"abstract":"One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He envisioned that a drug could specifically target a particular pathogen without affecting normal host cells. Antibody drug conjugates (ADCs) are the realization of Ehrlich’s vision for therapies that target tumor cells with precision and specificity.","PeriodicalId":500860,"journal":{"name":"ADC review","volume":"31 18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135719033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-19DOI: 10.14229/jadc.2023.09.19.015
Helge Grosch
Transitioning from lab manufacture to commercialization presents significant challenges, no matter what area you’re working in. Cell and gene therapies are no different and production quantities must scale at multiple stages, first to support clinical trials and then when they reach the market.
{"title":"What to Consider when Scaling Fill/Finish for Cell & Gene Therapy?","authors":"Helge Grosch","doi":"10.14229/jadc.2023.09.19.015","DOIUrl":"https://doi.org/10.14229/jadc.2023.09.19.015","url":null,"abstract":"Transitioning from lab manufacture to commercialization presents significant challenges, no matter what area you’re working in. Cell and gene therapies are no different and production quantities must scale at multiple stages, first to support clinical trials and then when they reach the market.","PeriodicalId":500860,"journal":{"name":"ADC review","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135016212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}